{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T10:46:13Z","timestamp":1777977973549,"version":"3.51.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T00:00:00Z","timestamp":1644796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T00:00:00Z","timestamp":1644796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001412","name":"Council\u00a0of\u00a0Scientific and Industrial Research, India","doi-asserted-by":"publisher","award":["08\/447(0001)\/2019-EMR-I"],"award-info":[{"award-number":["08\/447(0001)\/2019-EMR-I"]}],"id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010803","name":"Department of Biotechnology, Government of West Bengal","doi-asserted-by":"publisher","award":["6242-P57\/RGCB\/PMD\/DBT\/HPKR\/2015"],"award-info":[{"award-number":["6242-P57\/RGCB\/PMD\/DBT\/HPKR\/2015"]}],"id":[{"id":"10.13039\/501100010803","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s00280-022-04405-7","type":"journal-article","created":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T16:24:18Z","timestamp":1644855858000},"page":"393-400","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Evaluation of cytogenetic and molecular markers with MTX-mediated toxicity in pediatric acute lymphoblastic leukemia patients"],"prefix":"10.1007","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8255-5936","authenticated-orcid":false,"given":"Ravi","family":"Ramalingam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9535-5781","authenticated-orcid":false,"given":"Harpreet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julius Xavier","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Latha M.","family":"Sneha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ganeshprasad","family":"Arunkumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arathi","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0829-7780","authenticated-orcid":false,"given":"Solomon F. D.","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,14]]},"reference":[{"issue":"16","key":"4405_CR1","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1056\/nejmra1400972","volume":"373","author":"DL Longo","year":"2015","unstructured":"Longo DL, Hunger SP, Mullighan CG (2015) Acute lymphoblastic leukemia in children. N Engl J Med 373(16):1541\u20131552. https:\/\/doi.org\/10.1056\/nejmra1400972","journal-title":"N Engl J Med"},{"issue":"8","key":"4405_CR2","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/apt.13559","volume":"43","author":"W Moon","year":"2016","unstructured":"Moon W, Loftus EV (2016) Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease. Aliment Pharmacol Ther 43(8):863\u2013883. https:\/\/doi.org\/10.1111\/apt.13559","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"4405_CR3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.gpb.2016.11.003","volume":"15","author":"S Rudin","year":"2017","unstructured":"Rudin S, Marable M, Huang RS (2017) The promise of pharmacogenomics in reducing toxicity during acute lymphoblastic leukemia maintenance treatment. Genomics Proteomics Bioinformatics 15(2):82\u201393. https:\/\/doi.org\/10.1016\/j.gpb.2016.11.003","journal-title":"Genomics Proteomics Bioinformatics"},{"issue":"4","key":"4405_CR4","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2131\/jts.32.449","volume":"32","author":"K Fukino","year":"2007","unstructured":"Fukino K, Kawashima T, Suzuki M et al (2007) Methylenetetrahydrofolate reductase and reduced folate carrier-1 genotypes and methotrexate serum concentrations in patients with rheumatoid arthritis. J Toxicol Sci 32(4):449\u2013452. https:\/\/doi.org\/10.2131\/jts.32.449","journal-title":"J Toxicol Sci"},{"issue":"10","key":"4405_CR5","doi-asserted-by":"publisher","first-page":"3832","DOI":"10.1182\/blood.v100.10.3832","volume":"100","author":"C Laverdie","year":"2002","unstructured":"Laverdie C, Chiasson S, Costea I et al (2002) Brief report Polymorphism G 80 A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood 100(10):3832\u20133834. https:\/\/doi.org\/10.1182\/blood.v100.10.3832","journal-title":"Blood"},{"key":"4405_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2020.00307","author":"M Cwiklinska","year":"2020","unstructured":"Cwiklinska M, Czogala M, Kwiecinska K et al (2020) Polymorphisms of SLC19A1 80 G>A, MTHFR 677 C>T, and tandem TS repeats influence pharmacokinetics, acute liver toxicity, and vomiting in children with acute lymphoblastic leukemia treated with high doses of methotrexate. Front Pediatr. https:\/\/doi.org\/10.3389\/fped.2020.00307","journal-title":"Front Pediatr"},{"key":"4405_CR7","unstructured":"Whetstine JR, Gifford AJ, Witt T, et al (2001) Single nucleotide polymorphisms in the human reduced folate carrier: characterization of a high-frequency G\/A variant at position 80 and transport properties of the His27 and Arg27 carriers. Clin Cancer Res. 7(11):3416\u20133422. https:\/\/clincancerres.aacrjournals.org\/content\/7\/11\/3416.long"},{"issue":"8","key":"4405_CR8","doi-asserted-by":"publisher","first-page":"5069","DOI":"10.1007\/s11033-014-3372-6","volume":"41","author":"DO De Miranda","year":"2014","unstructured":"De Miranda DO, Barros JEXS, Vieira MMS et al (2014) Reduced folate carrier-1 G80a gene polymorphism is associated with neuroblastoma\u2019s development. Mol Biol Rep 41(8):5069\u20135075. https:\/\/doi.org\/10.1007\/s11033-014-3372-6","journal-title":"Mol Biol Rep"},{"key":"4405_CR9","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s00280-019-03776-8","volume":"4","author":"A Motassem","year":"2019","unstructured":"Motassem A, Rand Y, Daniah F et al (2019) Folate pathway genetic polymorphisms modulate methotrexate-induced toxicity in childhood acute lymphoblastic leukemia. Cancer Chemother Pharmacol 4:755\u2013762. https:\/\/doi.org\/10.1007\/s00280-019-03776-8","journal-title":"Cancer Chemother Pharmacol"},{"key":"4405_CR10","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v98.1.231","author":"CM Ulrich","year":"2013","unstructured":"Ulrich CM, Yasui Y, Storb R et al (2013) Pharmacogenetics of methotrexate\u202f: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism Brief report Pharmacogenetics of methotrexate\u202f: toxicity among marrow transplantation patients varies. Blood. https:\/\/doi.org\/10.1182\/blood.v98.1.231","journal-title":"Blood"},{"issue":"1\u20132","key":"4405_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.clinbiochem.2009.09.003","volume":"43","author":"N Karas-Kuzelicki","year":"2010","unstructured":"Karas-Kuzelicki N, Milek M, Mlinaric-Rascan I (2010) MTHFR and TYMS genotypes influence TPMT activity and its differential modulation in males and females. Clin Biochem 43(1\u20132):37\u201342. https:\/\/doi.org\/10.1016\/j.clinbiochem.2009.09.003","journal-title":"Clin Biochem"},{"issue":"2","key":"4405_CR12","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s12032-009-9232-x","volume":"27","author":"J Lazic","year":"2010","unstructured":"Lazic J, Tosic N, Dokmanovic L et al (2010) Clinical features of the most common fusion genes in childhood acute lymphoblastic leukemia. Med Oncol 27(2):449\u2013453. https:\/\/doi.org\/10.1007\/s12032-009-9232-x","journal-title":"Med Oncol"},{"issue":"5","key":"4405_CR13","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1182\/blood.v97.5.1219","volume":"97","author":"G Akpek","year":"2001","unstructured":"Akpek G, Zahurak ML, Piantadosi S et al (2001) Development of a prognostic model for grading chronic graft-versus-host disease. Blood 97(5):1219\u20131226. https:\/\/doi.org\/10.1182\/blood.v97.5.1219","journal-title":"Blood"},{"issue":"10","key":"4405_CR14","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1590\/s1807-59322011001000001","volume":"66","author":"MS Tamashiro","year":"2011","unstructured":"Tamashiro MS, Aikawa NE, Campos LMA et al (2011) Discrimination of acute lymphoblastic leukemia from systemic-onset juvenile idiopathic arthritis at disease onset. Clinics (Sao Paulo) 66(10):1665\u20131669. https:\/\/doi.org\/10.1590\/s1807-59322011001000001","journal-title":"Clinics (Sao Paulo)"},{"issue":"2","key":"4405_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.4103\/0971-5851.180144","volume":"37","author":"N Moulik","year":"2016","unstructured":"Moulik N, Kumar A, Agrawal S et al (2016) Effect of folate status and methylenetetrahydrofolate reductase genotypes on the complications and outcome of high dose methotrexate chemotherapy in north Indian children with acute lymphoblastic leukemia. Indian J Med Paediatr Oncol 37(2):85\u201389. https:\/\/doi.org\/10.4103\/0971-5851.180144","journal-title":"Indian J Med Paediatr Oncol"},{"issue":"5","key":"4405_CR16","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/tpj.2011.25","volume":"12","author":"J Salazar","year":"2012","unstructured":"Salazar J, Altes A, Del Rio E et al (2012) Methotrexate consolidation treatment according to pharmacogenetics of MTHFR ameliorates event-free survival in childhood acute lymphoblastic leukaemia. Pharmacogenomics J 12(5):379\u2013385. https:\/\/doi.org\/10.1038\/tpj.2011.25","journal-title":"Pharmacogenomics J"},{"issue":"5","key":"4405_CR17","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s13277-012-0395-2","volume":"33","author":"L Yang","year":"2012","unstructured":"Yang L, Hu X, Xu L (2012) Impact of methylenetetrahydrofolate reductase (MTHFR) polymorphisms on methotrexate-induced toxicities in acute lymphoblastic leukemia: a meta-analysis. Tumor Biol 33(5):1445\u20131454. https:\/\/doi.org\/10.1007\/s13277-012-0395-2","journal-title":"Tumor Biol"},{"issue":"5","key":"4405_CR18","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1186\/1479-7364-2-5-318","volume":"2","author":"AA Motsinger","year":"2006","unstructured":"Motsinger AA, Ritchie MD (2006) Multifactor dimensionality reduction: an analysis strategy for modelling and detecting gene-gene interactions in human genetics and pharmacogenomics studies. Hum Genomics 2(5):318\u2013328. https:\/\/doi.org\/10.1186\/1479-7364-2-5-318","journal-title":"Hum Genomics"},{"issue":"2","key":"4405_CR19","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1056\/nejmra052603","volume":"354","author":"C-H Pui","year":"2006","unstructured":"Pui C-H, Evans WE (2006) Treatment of acute lymphoblastic leukemia. N Engl J Med 354(2):166\u2013178. https:\/\/doi.org\/10.1056\/nejmra052603","journal-title":"N Engl J Med"},{"issue":"9881","key":"4405_CR20","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1016\/s0140-6736(12)62187-4","volume":"381","author":"H Inaba","year":"2013","unstructured":"Inaba H, Greaves M, Mullighan CG (2013) Acute lymphoblastic leukaemia. Lancet (London, England) 381(9881):1943\u20131955. https:\/\/doi.org\/10.1016\/s0140-6736(12)62187-4","journal-title":"Lancet (London, England)"},{"key":"4405_CR21","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/nejmra023001","volume":"15","author":"C Pui","year":"2004","unstructured":"Pui C, Relling M (2004) Acute lymphoblastic leukemia. N Engl J Med 15:1535\u20131548. https:\/\/doi.org\/10.1056\/nejmra023001","journal-title":"N Engl J Med"},{"issue":"5","key":"4405_CR22","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/j.1365-2141.2009.07765.x","volume":"146","author":"K Schmiegelow","year":"2009","unstructured":"Schmiegelow K (2009) Advances in individual prediction of methotrexate toxicity: a review. Br J Haematol 146(5):489\u2013503. https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07765.x","journal-title":"Br J Haematol"},{"issue":"6","key":"4405_CR23","doi-asserted-by":"publisher","first-page":"807","DOI":"10.2217\/pgs.13.244","volume":"15","author":"A Lima","year":"2014","unstructured":"Lima A, Bernardes M, Sousa H et al (2014) SLC19A1 80G allele as a biomarker of methotrexate-related gastrointestinal toxicity in Portuguese rheumatoid arthritis patients. Pharmacogenomics 15(6):807\u2013820. https:\/\/doi.org\/10.2217\/pgs.13.244","journal-title":"Pharmacogenomics"},{"issue":"4","key":"4405_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/genes11040468","volume":"11","author":"N Kotur","year":"2020","unstructured":"Kotur N, Lazic J, Ristivojevic B et al (2020) Pharmacogenomic markers of methotrexate response in the consolidation phase of pediatric acute lymphoblastic leukemia treatment. Genes (Basel) 11(4):1\u201317. https:\/\/doi.org\/10.3390\/genes11040468","journal-title":"Genes (Basel)"},{"issue":"2","key":"4405_CR25","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/01.mph.0000198269.61948.90","volume":"28","author":"N Shimasaki","year":"2006","unstructured":"Shimasaki N, Mori T, Samejima H et al (2006) Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol 28(2):64\u201368. https:\/\/doi.org\/10.1097\/01.mph.0000198269.61948.90","journal-title":"J Pediatr Hematol Oncol"},{"issue":"7","key":"4405_CR26","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1111\/bcp.13943","volume":"85","author":"R Choi","year":"2019","unstructured":"Choi R, Sohn I, Kim MJ et al (2019) Pathway genes and metabolites in thiopurine therapy in Korean children with acute lymphoblastic leukaemia. Br J Clin Pharmacol 85(7):1585\u20131597. https:\/\/doi.org\/10.1111\/bcp.13943","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"4405_CR27","doi-asserted-by":"publisher","first-page":"50","DOI":"10.5045\/br.2016.51.1.50","volume":"51","author":"JA Park","year":"2016","unstructured":"Park JA, Shin HY (2016) Influence of genetic polymorphisms in the folate pathway on toxicity after high-dose methotrexate treatment in pediatric osteosarcoma. Blood Res 51(1):50\u201357. https:\/\/doi.org\/10.5045\/br.2016.51.1.50","journal-title":"Blood Res"},{"key":"4405_CR28","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.intimp.2016.05.012","volume":"38","author":"X Li","year":"2016","unstructured":"Li X, Hu M, Li W et al (2016) The association between reduced folate carrier-1 gene 80G\/A polymorphism and methotrexate efficacy or methotrexate related-toxicity in rheumatoid arthritis: a meta-analysis. Int Immunopharmacol 38:8\u201315. https:\/\/doi.org\/10.1016\/j.intimp.2016.05.012","journal-title":"Int Immunopharmacol"},{"key":"4405_CR29","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s00228-011-1046-z","volume":"10","author":"BF Kotnik","year":"2011","unstructured":"Kotnik BF, Grabnar I (2011) Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma. Eur J Clin Pharmacol 10:993\u20131006. https:\/\/doi.org\/10.1007\/s00228-011-1046-z","journal-title":"Eur J Clin Pharmacol"},{"issue":"44","key":"4405_CR30","doi-asserted-by":"publisher","first-page":"33588","DOI":"10.1074\/jbc.m607049200","volume":"281","author":"Z Hou","year":"2006","unstructured":"Hou Z, Ye J, Haska CL et al (2006) Transmembrane domains 4, 5, 7, 8, and 10 of the human reduced folate carrier are important structural or functional components of the transmembrane channel for folate substrates. J Biol Chem 281(44):33588\u201333596. https:\/\/doi.org\/10.1074\/jbc.m607049200","journal-title":"J Biol Chem"},{"issue":"1","key":"4405_CR31","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/s0005-2736(01)00340-6","volume":"1513","author":"Y Wang","year":"2001","unstructured":"Wang Y, Zhao R, Russell RG et al (2001) Localization of the murine reduced folate carrier as assessed by immunohistochemical analysis. Biochimica et Biophysica Acta (BBA) - Biomembranes. 1513(1):49\u201354. https:\/\/doi.org\/10.1016\/s0005-2736(01)00340-6","journal-title":"Biochimica et Biophysica Acta (BBA) - Biomembranes."},{"issue":"13","key":"4405_CR32","doi-asserted-by":"publisher","first-page":"10224","DOI":"10.1074\/jbc.c000905200","volume":"276","author":"R Zhao","year":"2001","unstructured":"Zhao R, Russell RG, Wang Y et al (2001) Rescue of embryonic lethality in reduced folate carrier-deficient mice by maternal folic acid supplementation reveals early neonatal failure of hematopoietic organs. J Biol Chem 276(13):10224\u201310228. https:\/\/doi.org\/10.1074\/jbc.c000905200","journal-title":"J Biol Chem"},{"issue":"10","key":"4405_CR33","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1097\/fpc.0b013e328343dd93","volume":"21","author":"TS Mikkelsen","year":"2011","unstructured":"Mikkelsen TS, Thorn CF, Yang JJ et al (2011) PharmGKB summary: methotrexate pathway. Pharmacogenet Genomics 21(10):679\u2013686. https:\/\/doi.org\/10.1097\/fpc.0b013e328343dd93","journal-title":"Pharmacogenet Genomics"},{"issue":"7","key":"4405_CR34","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2217\/pgs-2020-0193","volume":"22","author":"R Ramalingam","year":"2021","unstructured":"Ramalingam R, Kaur H, Scott XS et al (2021) Pharmacogenetic evaluation of 6-mercaptopurine-mediated toxicity in pediatric acute lymphoblastic leukemia patients from a South Indian population. Pharmacogenomics 22(7):401\u2013411. https:\/\/doi.org\/10.2217\/pgs-2020-0193","journal-title":"Pharmacogenomics"},{"issue":"9","key":"4405_CR35","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1097\/00043426-200309000-00004","volume":"25","author":"AS Levy","year":"2003","unstructured":"Levy AS, Sather HN, Steinherz PG et al (2003) Reduced folate carrier and dihydrofolate reductase expression in acute lymphocytic leukemia may predict outcome: A Children\u2019s Cancer Group study. J Pediatr Hematol Oncol 25(9):688\u2013695. https:\/\/doi.org\/10.1097\/00043426-200309000-00004","journal-title":"J Pediatr Hematol Oncol"},{"issue":"11","key":"4405_CR36","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.2217\/pgs.14.97","volume":"15","author":"S Suthandiram","year":"2014","unstructured":"Suthandiram S, Gan G-G, Zain SM et al (2014) Effect of polymorphisms within methotrexate pathway genes on methotrexate toxicity and plasma levels in adults with hematological malignancies. Pharmacogenomics 15(11):1479\u20131494. https:\/\/doi.org\/10.2217\/pgs.14.97","journal-title":"Pharmacogenomics"},{"issue":"14","key":"4405_CR37","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.2217\/pgs.12.150","volume":"13","author":"P Bohanec Grabar","year":"2012","unstructured":"Bohanec Grabar P, Leandro-Garc\u00eda LJ, Inglada-P\u00e9rez L et al (2012) Genetic variation in the SLC19A1 gene and methotrexate toxicity in rheumatoid arthritis patients. Pharmacogenomics 13(14):1583\u20131594. https:\/\/doi.org\/10.2217\/pgs.12.150","journal-title":"Pharmacogenomics"},{"issue":"11\u201312","key":"4405_CR38","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1007\/s00439-019-02081-x","volume":"138","author":"L Schaller","year":"2019","unstructured":"Schaller L, Lauschke VM (2019) The genetic landscape of the human solute carrier (SLC) transporter superfamily. Hum Genet 138(11\u201312):1359\u20131377. https:\/\/doi.org\/10.1007\/s00439-019-02081-x","journal-title":"Hum Genet"},{"issue":"6","key":"4405_CR39","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1007\/s10067-017-3608-7","volume":"36","author":"N Muralidharan","year":"2017","unstructured":"Muralidharan N, Misra DP, Jain VK et al (2017) Effect of thymidylate synthase (TYMS) gene polymorphisms with methotrexate treatment outcome in south Indian Tamil patients with rheumatoid arthritis. Clin Rheumatol 36(6):1253\u20131259. https:\/\/doi.org\/10.1007\/s10067-017-3608-7","journal-title":"Clin Rheumatol"},{"issue":"9","key":"4405_CR40","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.2217\/pgs.12.70","volume":"13","author":"P Dorababu","year":"2012","unstructured":"Dorababu P, Naushad SM, Linga VG et al (2012) Genetic variants of thiopurine and folate metabolic pathways determine 6-MP-mediated hematological toxicity in childhood ALL. Pharmacogenomics 13(9):1001\u20131008. https:\/\/doi.org\/10.2217\/pgs.12.70","journal-title":"Pharmacogenomics"},{"issue":"January","key":"4405_CR41","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.lfs.2018.01.015","volume":"196","author":"SK Manche","year":"2018","unstructured":"Manche SK, Jangala M, Dudekula D et al (2018) Polymorphisms in folate metabolism genes are associated with susceptibility to presbycusis. Life Sci 196(January):77\u201383. https:\/\/doi.org\/10.1016\/j.lfs.2018.01.015","journal-title":"Life Sci"},{"key":"4405_CR42","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.gene.2017.06.023","volume":"627","author":"D Tiwari","year":"2017","unstructured":"Tiwari D, Das CR, Bose PD et al (2017) Associative role of TYMS6bpdel polymorphism and resulting hyperhomocysteinemia in the pathogenesis of preterm delivery and associated complications: a study from Northeast India. Gene 627:129\u2013136. https:\/\/doi.org\/10.1016\/j.gene.2017.06.023","journal-title":"Gene"},{"issue":"3","key":"4405_CR43","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1007\/s12032-011-9997-6","volume":"29","author":"NM EL-Khodary","year":"2012","unstructured":"EL-Khodary NM, EL-Haggar SM, Eid MA et al (2012) Study of the pharmacokinetic and pharmacogenetic contribution to the toxicity of high-dose methotrexate in children with acute lymphoblastic leukemia. Med Oncol 29(3):2053\u20132062. https:\/\/doi.org\/10.1007\/s12032-011-9997-6","journal-title":"Med Oncol"},{"issue":"8","key":"4405_CR44","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1038\/sj.jid.5700808","volume":"127","author":"E Campalani","year":"2007","unstructured":"Campalani E, Arenas M, Marinaki AM et al (2007) Polymorphisms in folate, pyrimidine, and purine metabolism are associated with efficacy and toxicity of methotrexate in psoriasis. J Invest Dermatol 127(8):1860\u20131867. https:\/\/doi.org\/10.1038\/sj.jid.5700808","journal-title":"J Invest Dermatol"},{"issue":"12","key":"4405_CR45","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s00277-008-0540-6","volume":"87","author":"K Soszynska","year":"2008","unstructured":"Soszynska K, Mucha B, Debski R et al (2008) The application of conventional cytogenetics, FISH, and RT-PCR to detect genetic changes in 70 children with ALL. Ann Hematol 87(12):991\u20131002. https:\/\/doi.org\/10.1007\/s00277-008-0540-6","journal-title":"Ann Hematol"},{"issue":"1","key":"4405_CR46","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/mph.0b013e318030ac4c","volume":"29","author":"H Ariffin","year":"2007","unstructured":"Ariffin H, Chen SP, Kwok CS et al (2007) Ethnic differences in the frequency of subtypes of childhood acute lymphoblastic leukemia: Results of the Malaysia-Singapore Leukemia Study Group. J Pediatr Hematol Oncol 29(1):27\u201331. https:\/\/doi.org\/10.1097\/mph.0b013e318030ac4c","journal-title":"J Pediatr Hematol Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-022-04405-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-022-04405-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-022-04405-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T15:07:01Z","timestamp":1645888021000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-022-04405-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,14]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["4405"],"URL":"https:\/\/doi.org\/10.1007\/s00280-022-04405-7","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,14]]},"assertion":[{"value":"11 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by Institutional ethics committee (internal code IEC-NI\/17\/JUN\/60\/70) and performed according to the international regulations in Good Clinical Practices and to the ethical principles of the Declaration of Helsinki. Written informed consent was obtained from all the patients or parents\/guardians whichever is applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from all the patients or parents\/guardians whichever is applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}